What's in Arbor Pharmaceuticals, Inc.'s pipeline?

Arbor Pharmaceuticals, Inc. has 6 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Arbor Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Medical University of Silesia, Bayer, Fifth Affiliated Hospital, Sun Yat-Sen University, Bristol-Myers Squibb, Chong Kun Dang Pharmaceutical.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/arbor-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Arbor Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arbor Pharmaceuticals, Inc. pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AR11	AR11	marketed			Other
BiDil XR	BiDil XR	marketed	Vasodilators	Vasculature and cardiac function	Cardiovascular
Placebo for Azilsartan Medoxomil	Placebo for Azilsartan Medoxomil	phase 3			Cardiovascular
Glycerin ear drops	Glycerin ear drops	phase 3	Osmotic agent		Otolaryngology
Azilsartan Medoxomil Low-dose	Azilsartan Medoxomil Low-dose	phase 3	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)	Cardiovascular

Therapeutic area mix

Cardiovascular · 3
Other · 1
Otolaryngology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Medical University of Silesia · 2 shared drug classes
Bayer · 1 shared drug class
Fifth Affiliated Hospital, Sun Yat-Sen University · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 shared drug class
Boryung Pharmaceutical Co., Ltd · 1 shared drug class
Baker Heart and Diabetes Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arbor Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Arbor Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arbor-pharmaceuticals-inc. Accessed 2026-06-10.